Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 901–1,000 of 1,000
Francis, G. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.068 · Cited by 8
“So, what is the role of the PCSK9-LDLR axis in predicting cardiovascular risk in patients with worsening heart failure? The authors remind us that heart failure hospitalization was reduced by rosuvastatin in CORONA (Controlled Rosuvastatin Multi-national Trial in Heart Failure) (4), and that other data support the hyp…”
BackgroundResultInfluentialKim, J., Hoang, T., Kim, J.-M., Bu, S. Y., Choi, J.-H., Park, E., Lee, S.-M., Park, E., Min, J. Y., Lee, I. S., et al. (2020) · Nutrients · doi:10.3390/nu12103203 · Cited by 8
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Rimskaya, E. M., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-2-6-76 · Cited by 8
Chen, H., Zhang, Y., Aikebaier, M., Du, Y., Liu, Y., Zha, Q., Zheng, L., Shan, S., Wang, Y., Chen, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202417489 · Cited by 13
Brunetti, N. D., Correale, M., Totaro, A., Ferraretti, A., Monaco, I., Passero, T., Gennaro, L. D., & Biase, M. D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.041 · Cited by 9
Bourantas, C. V., Loh, H. P., Sherwi, N., Tweddel, A. C., de Silva, R., Lukaschuk, E. I., Nicholson, A., Rigby, A. S., Thackray, S. D. R., Ettles, D. F., et al. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9284-9 · Cited by 9
“The CORONA study showed that treatment with statins does not improve the prognosis in patients with advanced heart failure overall [35].”
MethodSelf-citationTechorueangwiwat, C., Kanitsoraphan, C., & Hansrivijit, P. (2021) · F1000Research · doi:10.12688/f1000research.28254.1 · Cited by 10
Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy
Beltran, R. A., Zemeir, K., Kimberling, C. R., Kneer, M. S., Mifflin, M. D., & Broderick, T. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416899 · Cited by 10
Current experimental and early investigational agents for cardiac fibrosis: where are we at?
Ciampi, C. M., Sultana, A., Ossola, P., Farina, A., Fragasso, G., & Spoladore, R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326024 · Cited by 8
Kao, D. P., Martin, J. L., Aquilante, C. L., Shalowitz, E. L., Leyba, K. R., Kudron, E. L., Reusch, J. E. B., & Regensteiner, J. G. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004343 · Cited by 9
Beyond lipid lowering: pleiotropic effects of statins in heart failure
Swenne, C. A. (2013) · Netherlands Heart Journal · doi:10.1007/s12471-013-0460-5 · Cited by 8
Naegele, M., Flammer, A. J., Enseleit, F., & Ruschitzka, F. T. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14295 · Cited by 9
Arain, F., Gullestad, L. L., Nymo, S. H., KJEKSHUS, J. K., Cleland, J. G. F., Michelsen, A. E., McMurray, J. J. V., Wikstrand, J., Aukrust, P., & Ueland, T. (2016) · Biomarkers · doi:10.1080/1354750x.2016.1204003 · Cited by 8
Self-citationSteinberg, B. A., Mulpuru, S. K., Fang, J. C., & Gersh, B. J. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.09.025 · Cited by 8
Atkins, P., Pérez, H. A., Spence, J. D., Muñoz, S. E., Armando, L., & Garcia, N. H. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84677 · Cited by 8
Second revolution in cardiovascular prevention
Chiang, C., Wang, K.-L., Cheng, H., Sung, S., & Chao, T. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000276 · Cited by 8
Cui, X., Zhou, J., Pivodic, A., Dahlström, U., Ge, J., & Fu, M. L. X. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.02.048 · Cited by 9
Vieira, J. L., Pfeffer, M., Claggett, B. L., Stewart, G. C., Givertz, M. M., Coakley, L., Mallidi, H. R., & Mehra, M. R. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.02.017 · Cited by 8
The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs
Herrett, E. L., Williamson, E., Brack, K. E., Perkins, A., Thayne, A., Shakur‐Still, H., Roberts, I., Prowse, D., Beaumont, D., Jamal, Z., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25160 · Cited by 10
He, X., Dong, B., Liang, W., Wu, Y., Chen, Y., Dong, Y., He, J., & Liu, C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.013 · Cited by 9
Skendelas, J. P., Phan, D., Friedmann, P., Rodríguez, C. J., Stein, D. M., Arbab‐Zadeh, A., Forest, S., & Slipczuk, L. N. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023558 · Cited by 9
Sex/Gender Disparities in Randomized Controlled Trials of Statins: The Impact of Awareness Efforts
Farahani, P. (2014) · Clinical and investigative medicine · doi:10.25011/cim.v37i3.21383 · Cited by 8
Martin, J. H., Connelly, K. A., Boyle, A., Kompa, A. R., Zhang, Y., Kelly, D. J., Gilbert, R. E., & Krum, H. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.03.098 · Cited by 8
“The above observations must be viewed in the context of emerging clinical data on the utility of statins in chronic heart failure eg the (CORONA) [30] [46] and the GISSI-HF study.”
BackgroundNúñez, J. E., Sanchís, J. M., Núñez, E., Fonarow, G. C., Bodí, V., Bertomeu‐González, V., Miñana, G., Palau, P., Fácila, L., Chorro, F. J., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.029 · Cited by 9
Sumner, A. D., BOEHMER, J. P., Saxon, L. A., Carson, P. E., Feldman, A. M., Galle, E. G., & Bristow, M. R. (2009) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2009.00057.x · Cited by 8
Atorvastatin prevents type 2 diabetes mellitus—An experimental study
Madhu, S. V., Aslam, M., Galav, V., Bhattacharya, S. K., & Jafri, A. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.069 · Cited by 9
Mizuma, H., Inoue, T., Takano, H., Shindo, S., Oka, T., Fujimatsu, D., Kuwabara, Y., Node, K., & Komuro, I. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.022 · Cited by 8
Clinical Insights From the Treating to New Targets Trial
Waters, D. D. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.01.001 · Cited by 9
Team-Based Care for Managing Cardiac Comorbidities in Heart Failure
Bellam, N., Kelkar, A. A., & Whellan, D. J. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.03.005 · Cited by 9
Nicholls, S. J., Uno, K., & Kataoka, Y. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.145 · Cited by 11
Beneficial Effect of Atorvastatin on Renal Function in Patients with Type 2 Diabetes
Tanaka, M. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900440 · Cited by 7
Association between statin use, atherosclerosis, and mortality in HIV-infected adults
Phan, B. A. P., Ma, Y., Scherzer, R., Deeks, S. G., & Hsue, P. Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232636 · Cited by 9
Liu, Y., Hao, Z., Xiao, C., Liu, L., & Liao, H. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.70660 · Cited by 10
The Cornucopia of “Pleiotropic” Actions of Statins
Bolli, R., & Dawn, B. (2009) · Circulation Research · doi:10.1161/circresaha.108.192500 · Cited by 8
Statin treatment of rheumatoid arthritis: Comment on the editorial by Ridker and Solomon
Peters, M. J. L., Nurmohamed, M. T., Kitas, G. D., & Sattar, N. A. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25054 · Cited by 8
JUPITER: major implications for vascular risk assessment
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802643557 · Cited by 8
Beware of the hazards: limitations of the proportional hazards assumption
Cheung, C. C., Vittinghoff, E., Marcus, G. M., & Gerstenfeld, E. P. (2021) · EP Europace · doi:10.1093/europace/euab137 · Cited by 8
PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
Niessner, A., & Drexel, H. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab913 · Cited by 9
Kim, J. Y., Kim, N. H., Lee, J. Y., Kim, D., & Kim, S. G. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf053 · Cited by 10
Heart failure risk estimation based on novel biomarkers
Ataklte, F., & Vasan, R. S. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1933446 · Cited by 7
Lian, Z., Yu, S., Cui, Y.-X., Li, S., Su, L., Song, J.-X., Lee, C.-Y., Chen, Q., & Chen, H. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00151 · Cited by 7
The impact of statin use on short-term and long-term mortality in patients with heart failure
Zheng, X., Tan, L., & Zhang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1397763 · Cited by 7
Tsai, E. J., Wilkoff, B. L., Mitchell, J. E., Peterson, P. N., Riegel, B. J., Sam, F., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., et al. (2013) · Cited by 7
Ioffe, M., Kremer, A., Nachimov, I., Swartzon, M., & Justo, D. (2021) · Medicine · doi:10.1097/md.0000000000026966 · Cited by 9
Cholesterol Treatment Trialists’ Collaboration (2022) · Clinical Trials · doi:10.1177/17407745221105509 · Cited by 8
Significance of LDL-C lowering therapy in diabetic patients
Martinez-Hervas, M. S., Carmena, M. R., & Ascaso, M. J. F. (2011) · Clinical Lipidology · doi:10.2217/clp.11.28 · Cited by 7
Statins for heart failure: still caught in no man's land?
von Haehling, S. (2008) · Clinical Science · doi:10.1042/cs20080530 · Cited by 8
The Profile and Prognosis of Patients Hospitalised With Heart Failure
Špinar, J., Ludka, O., Musil, V., Pozdíšek, Z., Pavlík, T., Dušek, L., Vítovec, J., Špinarová, L., & Soucek, M. (2008) · International Heart Journal · doi:10.1536/ihj.49.691 · Cited by 7
Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?
Badimón, L., & Vilahur, G. (2011) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(11)12002-6 · Cited by 11
Standl, E. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112448876 · Cited by 7
Osteoprotegerin is a new marker of cardiovascular diseases
Verbovoy, A. F., Tsanava, I. A., Mitroshina, E. V., & Sharonova, L. A. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh201789491-94 · Cited by 7
Fröhlich, H., Raman, N., Täger, T., Schellberg, D., Goode, K. M., Kazmi, S., Grundtvig, M., Hole, T., Cleland, J. G. F., Katus, H. A., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.028 · Cited by 7
Self-citationZvizdi, F., Godinjak, A., Durak-Nalbantić, A., Rama, A., Iglica, A., Vučijak-Grgurević, M., & Sokolović, Š. (2018) · Medical Archives · doi:10.5455/medarh.2018.72.401-405 · Cited by 7
What the Guidelines Do Not Say: Statin Non-benefit Groups
Morris, P. B., & McLain, K. H. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0468-3 · Cited by 7
Statin-Mediated Low-Density Lipoprotein Lowering in Chronic Congestive Heart Failure
Kosmas, C. E., Alkhawam, H., El‐Hunjul, M., Wagman, G., Vittorio, T. J., Kahn, M. R., & Grady, K. M. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318273514c · Cited by 7
Prahl, U., Wikstrand, J., Bergström, G. M. L., Behre, C. J., Hulthe, J., & Fagerberg, B. (2010) · Angiology · doi:10.1177/0003319710370959 · Cited by 7
Self-citationHeintjes, E. M., Beest, F. J. A. P., Johansson, S., Stalenhoef, A. F. H., & Herings, R. M. C. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903269112 · Cited by 7
Rosuvastatin in Older Patients with Systolic Heart Failure
Cheitlin, M. D. (2009) · Yearbook of Cardiology · doi:10.1016/s0145-4145(08)79344-4 · Cited by 7
Ohte, N., & Little, W. C. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0016 · Cited by 7
Are statins failing in heart failure?: Figure 1
KJEKSHUS, J. K. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv133 · Cited by 7
Self-citationMitohormesis: another pleiotropic effect of statins?
Liao, J. K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr287 · Cited by 9
The significance of statin use in patients subjected to surgical coronary revascularization
Banach, M., Mikhailidis, D. P., Uğurlucan, M., Barylski, M., Banyś, A., Goch, A., & Goch, J. H. (2008) · UCL Discovery (University College London) · Cited by 7
Anderson, J. L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx386 · Cited by 7
Only Trials Tell the Truth About Treatment Effects
McMurray, J. J. V. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.019 · Cited by 7
Self-citationHeart Failure and Co-Morbidity Revisited; The Elephant in the Room
Wolsk, E. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1225 · Cited by 7
Statins Do More Than Lower Cholesterol—Depending on What You Eat?
Eschenhagen, T., & Laufs, U. (2021) · Circulation · doi:10.1161/circulationaha.121.054183 · Cited by 9
Statins for the primary prevention of venous thromboembolism
Wang, Z., Zhang, P., Tian, J., Zhang, P., Yang, K., & Li, L. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014769.pub2 · Cited by 12
Impact of Chronic Nitrate Therapy in Patients With Ischemic Heart Failure
Moreira-Silva, S., Urbano, J., Nogueira-Silva, L., Bettencourt, P., & Pimenta, J. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416634464 · Cited by 6
Liu, X., Zhu, H., Zheng, H., Sun, L., Qiu, M. R., & Huang, Y. (2022) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12507 · Cited by 7
Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events
Al-Ani, A., Jamil, Y., & Orkaby, A. R. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01139-4 · Cited by 7
Lim, T. H., Orija, I. B., & Pearlman, B. L. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2831 · Cited by 6
Long-term impact of secondary preventive treatments in patients with stable angina
Vokó, Z., de Brouwer, S., Lubsen, J. C., Danchin, N., Otterstad, J. E., Dunselman, P. H. J. M., & Kirwan, B. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9558-5 · Cited by 6
“population to sub-groups of that population [1].”
Self-citationLipid-lowering drugs and risk for cancer
Pedersen, T. R. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0053-3 · Cited by 6
Danchin, N. (2009) · Therapies · doi:10.2515/therapie/2009025 · Cited by 6
Statins in Heart Failure—Where Do We Stand?
Lyons, K., McVeigh, G. E., & Harbinson, M. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6269-1 · Cited by 6
Adjunctive Therapy and Management of the Transition of Care in Patients with Heart Failure
Feitell, S., Hankins, S. R., & Eisen, H. J. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.007 · Cited by 8
“Several trials have shown no benefit in patients with heart failure with reduced ejection fractions, regardless of cause.(22,23) Unless there are strong indications to start a statin, current data suggest withholding statin therapy in heart failure populations with reduced ejection fractions.”
BackgroundStatins in heart failure: Retrospective cohort study using routine primary care data
Ryan, R. P., McManus, R. J., Mant, J., Macleod, J., & Hobbs, R. F. (2009) · Annals of Medicine · doi:10.1080/07853890903022819 · Cited by 9
New Data on the Clinical Impact of Exercise Training, Fish Oils, and Statins in Heart Failure
Lavie, C. J., O’Keefe, J. H., Milani, R. V., Ventura, H. O., & Mehra, M. R. (2009) · The Physician and Sportsmedicine · doi:10.3810/psm.2009.06.1706 · Cited by 8
Low-dose digoxin and reduction in mortality and morbidity in heart failure
Ahmed, A., & Waagstein, F. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.06.083 · Cited by 6
Self-citationSankaranarayanan, R., Maini, S., James, M. A., Burtchaell, S., & Chatterjee, A. K. (2010) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2010.00165.x · Cited by 6
Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Algalarrondo, V., Boycott, H. E., Eliahou, L., Mabille, M., & Slama, M. (2013) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523011312010003 · Cited by 6
Kishimoto, I., Makino, H., Ohata, Y., Tamanaha, T., Tochiya, M., Anzai, T., KUSANO, K. F., Noguchi, T., Yasuda, S., & Ogawa, H. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000137 · Cited by 8
Reibis, R. K., Jannowitz, C., Halle, M., Pittrow, D. B., Gitt, A. K., & Völler, H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.977854 · Cited by 8
Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol
Tsujimoto, T., Kajio, H., & Sugiyama, T. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.08.011 · Cited by 6
Lee, Y. P., Cho, Y., Kim, E. J., Lee, H., Choi, H. Y., Wang, H. J., Kang, E. S., Kim, Y. S., Kim, M. S., & Kim, B. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-39461-2 · Cited by 6
Borne, E., Meyer, N., Rybarczyk-Vigouret, M.-C., Blanchard, O., Lombard, M., Lang, P. O., Vogel, T., & Michel, B. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00695-4 · Cited by 7
Domecq, J. P., Prutsky, G. J., Elraiyah, T. A., Wang, Z., Mauck, K. F., Brito, J. P., Undavalli, C., Sundaresh, V., Prokop, L. J., Montori, V. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01269 · Cited by 8
REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed
Rohde, L. E. P., & McMurray, J. J. V. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad488 · Cited by 8
Self-citationHalcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 6
Jeong, H. C., Ahn, Y., Park, K. H., Sim, D. S., Hong, Y. J., Kim, J. H., Jeong, M. H., Kim, Y. J., Chae, S. C., Cho, M., et al. (2014) · International Heart Journal · doi:10.1536/ihj.13-223 · Cited by 6
Lipid-Modifying Treatments for Heart Failure
Cleland, J. G. F., Hutchinson, K., Pellicori, P., & Clark, A. L. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.07.006 · Cited by 6
Self-citationGrander, W., & Dünser, M. W. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.01.020 · Cited by 7
“hospitalizations [44].”
Antithrombotic Therapy in Heart Failure
Konstam, M. A. (2009) · Circulation · doi:10.1161/circulationaha.109.850198 · Cited by 6
van der Harst, P., Slart, R. H. J. A., Tio, R. A., Dunselman, P. H. J. M., Willemsen, A. T. M., van den Heuvel, A. F. M., Voors, A. A., & van Veldhuisen, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.021 · Cited by 6
Self-citationDiscrepancy between results of randomized control studies and retrospective analysis
Nevzorov, R., Novack, V., Henkin, Y., Kobal, S. L., Jotkowitz, A., & Porath, A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.03.001 · Cited by 6
“However, the latest large prospective randomized placebo controlled trials with rosuvastatin (CORONA) and (GISSIHF), showed no reduction in clinical outcomes in different groups of patients with HF [6,20].”
BackgroundStatins and Advanced Heart Failure—Alive But Barely Breathing After CORONA and GISSI‐HF
Lavie, C. J., & Mehra, M. R. (2009) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2009.00089.x · Cited by 6
The Great Debate of 2008—How Low to Go in Preventive Cardiology?
Peterson, E. D., & Wang, T. Y. (2008) · JAMA · doi:10.1001/jama.299.14.1718 · Cited by 6
Tailored therapy for heart failure: the role of biomarkers
Wollert, K. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs129 · Cited by 6
Statin Therapy in Heart Failure
Javaheri, A., Rader, D. J., & Javaheri, S. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02703 · Cited by 6
Revascularization in Ischemic Left Ventricular Dysfunction
Ryan, M., Truesdell, A. G., Murphy, G. J., Ezad, S. M., Fremes, S. E., Lansky, A. J., Ömerovic, E., Windecker, S., Velazquez, E. J., Petrie, M. C., et al. (2025) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2025.10.030 · Cited by 7
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.